ERBB2 and prostate carcinoma: A number of studies in prostate cancer have demonstrated that NDRG1 associates with androgen receptors and inhibits a range of critical signalling pathways, including EGFR, HER2, HER3, PI3K, and STAT3 [37,38,39,40].